Search Within

Erel Joffe

Formats
  1. Meeting Abstract (56)
  2. Journal Article (23)
  3. Research Letter (3)
  4. Review (2)
Groups
  1. Department of Medicine (84)
  2. Hematologic Malignancies, Division of (84)
  3. Sloan Kettering Institute Postdocs (84)
  4. Survivorship Research (56)
  5. Center for Hematologic Malignancies (50)
  6. Lymphoma (49)

More Groups

People
  1. Andrew Zelenetz (46)
  2. Ariela Noy (41)
  3. Maria Palomba (41)
  4. Matthew Matasar (38)
  5. Connie Batlevi (36)
  6. Paul Hamlin (36)

More People

Years
  1. 2024 (5)
  2. 2023 (9)
  3. 2022 (14)
  4. 2021 (22)
  5. 2020 (18)
  6. 2019 (13)

More Years

Publications
  1. Blood (31)
  2. Hematological Oncology (10)
  3. Journal of Clinical Oncology (9)
  4. Blood Advances (6)
  5. Blood Cancer Journal (4)
  6. International Journal of Radiation Oncology, Biology, Physics (3)

More Publications

Publishers
  1. American Society of Hematology (37)
  2. Wiley Blackwell (10)
  3. American Society of Clinical Oncology (9)
  4. Elsevier Inc. (8)
  5. Nature Publishing Group (5)
  6. Taylor & Francis Group (3)

More Publishers

Results (84)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T: Comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Fleury, I.; Peters, A.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: An international retrospective study of 2300 high-risk patients
    Meeting Abstract

    Lewis, K. L.; Jakobsen, L. H.; Villa, D.; Bobillo, S.; Smedby, K. E.; Savage, K. J.; Eyre, T. A.; Cwynarski, K.; Caporn, P. L.; Van Zyl, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Nanatinostat (Nstat) and valganciclovir (VGCV) in relapsed/refractory (R/R) Epstein-Barr virus-positive (EBV (+)) lymphomas: Final results from the phase 1b/2 VT3996-201 study
    Meeting Abstract

    Haverkos, B. M.; Alpdogan, O.; Baiocchi, R.; Brammer, J. E.; Feldman, T. A.; Capra, M.; Brem, E. A.; Nair, S. M.; Scheinberg, P.; Pereira, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The outcome of CLL patients according to IGHV mutational status: An Israeli perspective
    Meeting Abstract

    Bronstein, Y.; Levi, S.; Tsuriel, S.; Arbel, Y. S.; Joffe, E.; Herishanu, Y.
    Blood (2021)

    Fulltext@MSK | Save
  • Predictors of response to very low dose radiotherapy (4Gy) for indolent B-cell lymphomas: Is 4Gy also suitable for potentially curable patients?
    Meeting Abstract

    Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Chelius, M.; Hajj, C.; Wijetunga, N. A.; Yang, J. C.; Casey, D. L.; Shepherd, A. F.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save